CRIS Current Research Information System

GUGLIOTTA, GABRIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 6.111
NA - Nord America 6.067
EU - Europa 4.063
SA - Sud America 376
AF - Africa 335
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 2
Totale 16.968
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.989
VN - Vietnam 1.710
SG - Singapore 1.608
CN - Cina 1.503
GB - Regno Unito 1.165
IT - Italia 577
DE - Germania 483
SE - Svezia 476
HK - Hong Kong 359
NL - Olanda 298
BR - Brasile 272
FR - Francia 259
IN - India 256
RU - Federazione Russa 218
KR - Corea 144
IE - Irlanda 141
BD - Bangladesh 135
UA - Ucraina 110
JP - Giappone 107
ZA - Sudafrica 95
TG - Togo 82
EE - Estonia 72
FI - Finlandia 62
CI - Costa d'Avorio 56
JO - Giordania 51
BG - Bulgaria 50
CA - Canada 49
NG - Nigeria 38
AR - Argentina 36
PH - Filippine 34
CH - Svizzera 33
ID - Indonesia 30
TH - Thailandia 28
IQ - Iraq 27
AT - Austria 26
BE - Belgio 25
SC - Seychelles 21
PL - Polonia 19
MX - Messico 18
EC - Ecuador 17
IR - Iran 17
TW - Taiwan 17
TR - Turchia 15
PK - Pakistan 14
AU - Australia 13
CL - Cile 12
ES - Italia 12
VE - Venezuela 11
CO - Colombia 10
UZ - Uzbekistan 9
IL - Israele 7
MA - Marocco 7
SA - Arabia Saudita 7
LB - Libano 6
MY - Malesia 6
PE - Perù 6
PY - Paraguay 6
TN - Tunisia 6
CZ - Repubblica Ceca 5
ET - Etiopia 5
GR - Grecia 5
KE - Kenya 5
RO - Romania 5
AE - Emirati Arabi Uniti 4
DK - Danimarca 4
EG - Egitto 4
LT - Lituania 4
LY - Libia 4
NO - Norvegia 4
UY - Uruguay 4
NP - Nepal 3
AL - Albania 2
AZ - Azerbaigian 2
CR - Costa Rica 2
DZ - Algeria 2
GE - Georgia 2
GM - Gambi 2
GT - Guatemala 2
HN - Honduras 2
JM - Giamaica 2
LA - Repubblica Popolare Democratica del Laos 2
MU - Mauritius 2
PS - Palestinian Territory 2
PT - Portogallo 2
RS - Serbia 2
SY - Repubblica araba siriana 2
ZM - Zambia 2
AO - Angola 1
BO - Bolivia 1
CY - Cipro 1
EU - Europa 1
KW - Kuwait 1
KZ - Kazakistan 1
LC - Santa Lucia 1
LV - Lettonia 1
MD - Moldavia 1
MK - Macedonia 1
MM - Myanmar 1
NZ - Nuova Zelanda 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 16.961
Salva come PNG Salva come JPEG
Città #
Singapore 1.145
Southend 1.072
Ashburn 687
Fairfield 606
Chandler 473
Ho Chi Minh City 397
San Jose 377
Hanoi 367
Hong Kong 335
Woodbridge 298
Wilmington 295
Houston 291
Hefei 277
Seattle 277
Beijing 242
Dong Ket 226
Cambridge 220
Princeton 201
Ann Arbor 170
Dublin 141
Boardman 136
Seoul 125
Bologna 123
Lauterbourg 108
Santa Clara 106
Nanjing 102
Tokyo 87
Westminster 83
Lomé 82
New York 81
Los Angeles 79
Padova 71
Berlin 64
Dallas 57
Abidjan 56
Buffalo 54
Haiphong 54
Helsinki 52
Da Nang 51
Jinan 50
Sofia 50
Milan 49
Amman 48
Shenyang 45
Jacksonville 42
Redondo Beach 42
Frankfurt am Main 41
Abeokuta 37
Changsha 37
Turin 37
São Paulo 35
Saint Petersburg 33
Bengaluru 31
Council Bluffs 29
Shanghai 29
Nanchang 28
San Diego 28
Tianjin 28
Bern 27
Biên Hòa 26
Guangzhou 25
Medford 25
Brussels 24
Falls Church 24
Redmond 24
Jiaxing 23
Munich 22
Nuremberg 22
Zhengzhou 22
Des Moines 21
Hebei 21
Orem 21
Rome 20
The Dalles 20
Bremen 19
Chicago 19
London 18
Mountain View 18
Norwalk 17
Chengdu 16
Hangzhou 16
Baghdad 15
Dearborn 15
Montreal 15
Phoenix 15
Warsaw 15
Boston 14
Can Tho 14
Hải Dương 14
Ninh Bình 14
Toronto 14
Bắc Ninh 13
Falkenstein 13
Ha Long 13
Jakarta 13
Taizhou 13
Haikou 12
Ningbo 12
Paris 12
Bắc Giang 11
Totale 11.134
Salva come PNG Salva come JPEG
Nome #
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia 389
IL-18 and VEGF-A trigger type 2 innate lymphoid cell accumulation and pro-tumoral function in chronic myeloid leukemia 386
A calpain-cleaved fragment of β-catenin promotes BCRABL1+ cell survival evoked by autophagy induction in response to imatinib 275
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis 253
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 232
No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib 230
Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors 228
Chibby drives β catenin cytoplasmic accumulation leading to activation of the unfolded protein response in BCR-ABL1+ cells 220
Chibby 1: A new component of β-catenin-signaling in chronic myeloid leukemia 220
A review and an update of European leukemianet recommendations for the management of chronic myeloid leukemia 220
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 214
Efficacy and Safety of Frontline Single‐Agent Rituximab in Extranodal Marginal Zone Lymphoma 208
At the time of diagnosis, Ph cells from both chronic phase chronic myeloid leukemia and acute lymphoblastic leukemia patients already harbour BCR-ABL kinase domain mutations 204
BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS 203
Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms 200
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: Effects on response rate, toxicity and outcome 199
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview 199
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 198
Anagrelide treatment and cardiovascular monitoring in essential thrombocythemia. A prospective observational study 197
TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA 191
Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells 190
Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. 189
Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients 188
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 185
The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy 184
A review of the European LeukemiaNet recommendations for the management of CML 180
Long-term efficacy of immune checkpoint inhibitors for relapsed primary mediastinal B-cell lymphoma: a real-world study 177
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. 176
FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage 173
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart 171
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. 170
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. 169
Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia 168
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia 168
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. 167
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study 165
FOXM1 Transcription Factor Is a Component of Beta Catenin Signaling in Hematopoietic Progenitors of Chronic Myeloid Leukemia 165
Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axis 162
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants 160
Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison. 159
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 159
Deep sequencing of the BCR-ABL kinase domain reveals a frequency of 35INS insertion/truncation higher than expected 159
Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia 157
Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors 157
Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides. 157
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib 156
The Treatment of Burkitt Lymphoma With the Berlin-Frankfurt-Münster Protocol With Rituximab and Consolidative Autologous Transplantation 155
Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey 154
Prospective assessment of NGS-detectable mutations in CML patients with non-optimal response: the NEXT-in-CML study 152
High Sensitivity Mutation Monitoring and Clonal Analysis by Ultra-Deep Amplicon Sequencing Uncover the Complexity of BCR-ABL Mutation Status in Philadelphia+ Patients Treated with Tyrosine Kinase Inhibitors 150
Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors. 150
DNA methyltransferase 1 drives transcriptional down-modulation of β catenin antagonist Chibby1 associated with the BCR-ABL1 gene of chronic myeloid leukemia. 150
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. 150
Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib 147
Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia 146
Tyrosine kinase inhibitors in chronic myeloid leukaemia: Which, when, for whom? 145
High frequency of small insertions and deletions in the BCR-ABL Kinase Domain revealed by ultra-deep sequencing 145
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. 142
Diagnosis and classification of the risk 141
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series 141
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 141
Valosin-Containing Protein/p97 as a Novel Therapeutic Target in Acute Lymphoblastic Leukemia 140
Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy 140
Validation of the New European LeukemiaNet (ELN) Recommendations for Bcr-Abl Kinase Domain Mutation Analysis In Chronic Myeloid Leukemia: An Analysis of the GIMEMA CML Working Party Studies 139
Resistance to second-line tyrosine kinase inhibitor treatment in imatinib-resistant Philadelphia-positive leukemia patients can be anticipated by ultra-deep sequencing of the BCR-ABL kinase domain using Roche 454 technology 139
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. 138
Positive Selection and Transplantation of Autologous Highly Purified CD133+ Stem Cells in Resistant/Relapsed Chronic Lymphocytic Leukemia Patients Results in Rapid Hematopoietic Reconstitution without an Adequate Leukemic Cell Purging 136
High Sensitivity Mutation Screening and Clonal Analysis Allowed by Ultra-Deep Amplicon Sequencing Uncover the Complexity of Bcr-Abl Mutation Status in Patients Treated with Tyrosine Kinase Inhibitors 135
Further strategies after immune checkpoint inhibitors in relapsed/refractory Hodgkin lymphoma: salvage treatments and consolidation with transplantation, experience in daily clinical practice 134
Essential role of lyn in fibrosis 134
Ultrasound-guided core needle biopsy of nodular lesions of the spleen in hematology clinical practice 133
Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials 131
Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients. 128
Managing chronic myeloid leukemia for treatment-free remission: A proposal from the GIMEMA CML WP 128
Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia 125
First-Line Treatment of Newly Diagnosed Elderly Patients with Chronic Myeloid Leukemia: Current and Emerging Strategies 125
Observational study of chronic myeloid leukemia italian patients who discontinued tyrosine kinase inhibitors in clinical practice 125
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients 125
F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib 124
Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia 123
Frontline Treatment of Philadelphia Positive Chronic Myeloid Leukemia with Sequential Administration of Nilotinib 400 Mg Twice Daily and Imatinib 400 Mg Once Daily: a Phase 2 Multicentric Study 122
Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain 122
EARLY PREDICTORS OF PROGRESSION TO ACCELERATED-BLASTIC PHASE IN EARLY CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS TREATED FRONTLINE WITH NILOTINIB-BASED REGIMENS 119
Safety profiles of first-line TKIS and managing adverse effects 119
Differences among young adults, adults and elderly chronic myeloid leukemia patients 117
Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain 117
Imatinib in Very Elderly Patients with Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Study 117
SARS-CoV-2 infection does not affect the outcome of patients with relapsed/refractory large B-cell lymphoma treated with CAR T-cell therapy 116
Current treatment approaches in CML. 116
Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase 115
Physician’s guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML 113
Deep sequencing of the bcr-abl kinase domain reveals a high frequency of bcr-abl35-ins insertion/truncation mutation in chronic myeloid leukemia and Philadelphia positive acute lymphoblastic leukemia patients 113
NILOTINIB 400 MG BID IN EARLY CHRONIC PHASE CHRONIC MYELOID LEUKEMIA: BEYOND 4 YEARS RESULTS REMAIN STABLE - THE GIMEMA CML WP TRIAL CML0307 112
CML-184 A Novel Droplet Digital PCR Strategy for Rapid and Sensitive Detection of BCR::ABL1 Kinase Domain Mutations Conferring Resistance to Second-Generation Tyrosine Kinase Inhibitors 109
COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report 108
EUTOS SCORE IS PREDICTIVE FOR SURVIVAL AND OUTCOME IN PATIENTS WITH EARLY CHRONIC PHASE CHRONIC MYELOID LEUKEMIA TREATED WITH NILOTINIB-BASED REGIMENS 106
Chronic myeloid leukemia. Drug selection in first-line therapy and beyond 106
Thyrosin kinase inhibitors: nilotinib 97
Pancreatic enzymes elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure 97
Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools 93
Totale 16.022
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.632
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.632
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021404 0 0 0 0 0 0 0 0 0 0 0 404
2021/20221.674 153 57 137 140 170 99 27 97 83 103 286 322
2022/20231.961 198 299 107 240 156 140 87 122 341 35 159 77
2023/2024507 27 83 36 55 47 116 25 19 23 32 18 26
2024/20252.352 66 357 205 164 267 106 148 63 32 366 119 459
2025/20266.075 696 667 532 445 569 288 556 278 1.132 468 261 183
Totale 17.304